Selected Clinical Features of Coccidioidomycosis in Dogs

Autumn P. Davidson, Lisa F. Shubitz, Cody J. Alcott, Jane E Sykes

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Canine coccidioidomycosis, a systemic fungal infection endemic to arid and semiarid regions of North, Central, and South America, is commonly diagnosed in dogs living in or traveling through lower Sonoran life zones in the states of California and Arizona. Canine and human cases have geographic overlap. Similarities between clinical coccidioidomycosis in dogs and humans include asymptomatic infection, primary respiratory disease and disseminated disease. Differences include a high rate of dissemination in dogs, differences in predilection of dissemination sites, and a granulomatous or diffuse meningoencephalopathic form in the canine central nervous system (CNS) without the obstructive component seen in humans. Dogs presenting with CNS coccidioidomycosis most commonly experience seizures. Prior disease history and serology are unreliable indicators of CNS coccidioidomycosis. Magnetic resonance imaging (MRI) is advantageous for diagnosis of CNS coccidioidomycosis in dogs. Long-term administration of antifungal medication is promoted for treatment of both primary and disseminated coccidioidomycosis in dogs. Supportive treatment addressing pain, fever, inappetance, coughing, and other clinical signs improves patient care. Glucocorticoids and or anticonvulsants are also recommended for canine disseminated CNS disease. Protracted treatment times, lack of owner compliance, failure of the disease to respond to the first antifungal drug selected, and high cost are challenges of successfully treating dogs.

Original languageEnglish (US)
Pages (from-to)S67-S75
JournalMedical Mycology
Volume57
Issue number1
DOIs
StatePublished - Feb 1 2019

Fingerprint

Coccidioidomycosis
Dogs
Canidae
Central Nervous System
Central America
Asymptomatic Infections
Mycoses
South America
Central Nervous System Diseases
Serology
North America
Anticonvulsants
Glucocorticoids
Compliance
Patient Care
Seizures
Fever
Therapeutics
Magnetic Resonance Imaging
Costs and Cost Analysis

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Selected Clinical Features of Coccidioidomycosis in Dogs. / Davidson, Autumn P.; Shubitz, Lisa F.; Alcott, Cody J.; Sykes, Jane E.

In: Medical Mycology, Vol. 57, No. 1, 01.02.2019, p. S67-S75.

Research output: Contribution to journalArticle

Davidson, AP, Shubitz, LF, Alcott, CJ & Sykes, JE 2019, 'Selected Clinical Features of Coccidioidomycosis in Dogs', Medical Mycology, vol. 57, no. 1, pp. S67-S75. https://doi.org/10.1093/mmy/myy113
Davidson, Autumn P. ; Shubitz, Lisa F. ; Alcott, Cody J. ; Sykes, Jane E. / Selected Clinical Features of Coccidioidomycosis in Dogs. In: Medical Mycology. 2019 ; Vol. 57, No. 1. pp. S67-S75.
@article{5c80a1b5d36a4c508c12a690e46e0e09,
title = "Selected Clinical Features of Coccidioidomycosis in Dogs",
abstract = "Canine coccidioidomycosis, a systemic fungal infection endemic to arid and semiarid regions of North, Central, and South America, is commonly diagnosed in dogs living in or traveling through lower Sonoran life zones in the states of California and Arizona. Canine and human cases have geographic overlap. Similarities between clinical coccidioidomycosis in dogs and humans include asymptomatic infection, primary respiratory disease and disseminated disease. Differences include a high rate of dissemination in dogs, differences in predilection of dissemination sites, and a granulomatous or diffuse meningoencephalopathic form in the canine central nervous system (CNS) without the obstructive component seen in humans. Dogs presenting with CNS coccidioidomycosis most commonly experience seizures. Prior disease history and serology are unreliable indicators of CNS coccidioidomycosis. Magnetic resonance imaging (MRI) is advantageous for diagnosis of CNS coccidioidomycosis in dogs. Long-term administration of antifungal medication is promoted for treatment of both primary and disseminated coccidioidomycosis in dogs. Supportive treatment addressing pain, fever, inappetance, coughing, and other clinical signs improves patient care. Glucocorticoids and or anticonvulsants are also recommended for canine disseminated CNS disease. Protracted treatment times, lack of owner compliance, failure of the disease to respond to the first antifungal drug selected, and high cost are challenges of successfully treating dogs.",
author = "Davidson, {Autumn P.} and Shubitz, {Lisa F.} and Alcott, {Cody J.} and Sykes, {Jane E}",
year = "2019",
month = "2",
day = "1",
doi = "10.1093/mmy/myy113",
language = "English (US)",
volume = "57",
pages = "S67--S75",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Selected Clinical Features of Coccidioidomycosis in Dogs

AU - Davidson, Autumn P.

AU - Shubitz, Lisa F.

AU - Alcott, Cody J.

AU - Sykes, Jane E

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Canine coccidioidomycosis, a systemic fungal infection endemic to arid and semiarid regions of North, Central, and South America, is commonly diagnosed in dogs living in or traveling through lower Sonoran life zones in the states of California and Arizona. Canine and human cases have geographic overlap. Similarities between clinical coccidioidomycosis in dogs and humans include asymptomatic infection, primary respiratory disease and disseminated disease. Differences include a high rate of dissemination in dogs, differences in predilection of dissemination sites, and a granulomatous or diffuse meningoencephalopathic form in the canine central nervous system (CNS) without the obstructive component seen in humans. Dogs presenting with CNS coccidioidomycosis most commonly experience seizures. Prior disease history and serology are unreliable indicators of CNS coccidioidomycosis. Magnetic resonance imaging (MRI) is advantageous for diagnosis of CNS coccidioidomycosis in dogs. Long-term administration of antifungal medication is promoted for treatment of both primary and disseminated coccidioidomycosis in dogs. Supportive treatment addressing pain, fever, inappetance, coughing, and other clinical signs improves patient care. Glucocorticoids and or anticonvulsants are also recommended for canine disseminated CNS disease. Protracted treatment times, lack of owner compliance, failure of the disease to respond to the first antifungal drug selected, and high cost are challenges of successfully treating dogs.

AB - Canine coccidioidomycosis, a systemic fungal infection endemic to arid and semiarid regions of North, Central, and South America, is commonly diagnosed in dogs living in or traveling through lower Sonoran life zones in the states of California and Arizona. Canine and human cases have geographic overlap. Similarities between clinical coccidioidomycosis in dogs and humans include asymptomatic infection, primary respiratory disease and disseminated disease. Differences include a high rate of dissemination in dogs, differences in predilection of dissemination sites, and a granulomatous or diffuse meningoencephalopathic form in the canine central nervous system (CNS) without the obstructive component seen in humans. Dogs presenting with CNS coccidioidomycosis most commonly experience seizures. Prior disease history and serology are unreliable indicators of CNS coccidioidomycosis. Magnetic resonance imaging (MRI) is advantageous for diagnosis of CNS coccidioidomycosis in dogs. Long-term administration of antifungal medication is promoted for treatment of both primary and disseminated coccidioidomycosis in dogs. Supportive treatment addressing pain, fever, inappetance, coughing, and other clinical signs improves patient care. Glucocorticoids and or anticonvulsants are also recommended for canine disseminated CNS disease. Protracted treatment times, lack of owner compliance, failure of the disease to respond to the first antifungal drug selected, and high cost are challenges of successfully treating dogs.

UR - http://www.scopus.com/inward/record.url?scp=85060584929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060584929&partnerID=8YFLogxK

U2 - 10.1093/mmy/myy113

DO - 10.1093/mmy/myy113

M3 - Article

C2 - 30690600

AN - SCOPUS:85060584929

VL - 57

SP - S67-S75

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

IS - 1

ER -